|
|
|
|
Bluebird Bio Inc (NASDAQ: BLUE) |
|
Price: $4.9700
$0.00 
0.000%
|
| Day's High:
| $5.03
| Week Perf:
| -0.4 %
|
| Day's Low: |
$ 4.67 |
30 Day Perf: |
21.81 % |
| Volume (M): |
1,245,100 |
52 Wk High: |
$ 0.00 |
| Volume (M$): |
$ 6,188 |
52 Wk Avg: |
$0.00 |
| Open: |
$4.74 |
52 Wk Low: |
$0.00 |
|
|
| Market Capitalization (Millions $) |
48 |
| Shares
Outstanding (Millions) |
10 |
| Employees |
248 |
| Revenues (TTM) (Millions $) |
104 |
| Net Income (TTM) (Millions $) |
139 |
| Cash Flow (TTM) (Millions $) |
-172 |
| Capital Exp. (TTM) (Millions $) |
2 |
Business Description
Bluebird Bio Inc. is a biotechnology company that develops gene therapies for severe genetic diseases and cancer. The company is known for its focus on using gene therapy to treat inherited blood disorders, such as beta-thalassemia and sickle cell disease. Bluebird Bio also develops CAR-T cell therapies for various types of cancer. The company's gene therapies involve modifying a patient's own cells to correct or replace the faulty gene responsible for the disease. Bluebird Bio aims to provide long-lasting and potentially curative treatment options for patients suffering from these devastating conditions.
Company Address: 455 Grand Union Boulevard Somerville 2145 MA
Company Phone Number: 499-9300 Stock Exchange / Ticker: NASDAQ BLUE
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Tue, May 6 2025 7:39 AM UTC
Bluebird bio, Inc. a biotechnology company focused on gene therapies, has successfully navigated the regulatory landscape to finalize its acquisition by Carlyle Group and SK Capital Partners. This merger, announced earlier this year, is set against a backdrop of extraordinary financial performance for Bluebird, which reported a significant year-on-year revenue increase. Th...
|
| Business Update
Published Wed, Apr 16 2025 4:39 PM UTC
Bluebird Bio Reaffirms Commitment to Carlyle and SK Capital Amidst Unfulfilled Engagement with Ayrmid Ltd. Somerville, Mass. In a recent announcement, bluebird bio, Inc. (NASDAQ: BLUE) has confirmed that Ayrmid Ltd. has failed to deliver a binding offer or secure necessary financing for the proposed acquisition, despite a period of extensive discussions that lasted three...
|
| Business Update
Published Fri, Feb 21 2025 2:41 PM UTC
Bluebird Bio, Inc. (NASDAQ: BLUE), a biotechnology company known for its innovative approaches to gene therapy, recently announced a definitive agreement to be acquired by global investment firms Carlyle and SK Capital Partners, LP. This strategic move comes amid a challenging period for Bluebird, as its shares have been trailing the broader market and failing to keep pace w...
|
| Business Update
Published Sat, Dec 7 2024 6:47 PM UTC
Gene Therapy Breakthrough Offers Hope for Beta-Thalassemia Patients SOMERVILLE, Mass. bluebird bio, Inc. (Nasdaq: BLUE) has announced promising long-term follow-up data indicating that betibeglogene autotemcel (commonly known as beti-cel and marketed as ZYNTEGLO) could offer curative potential for patients with beta-thalassemia. This condition, characterized by the need fo...
|
| Business Update
Published Wed, Dec 4 2024 4:47 PM UTC
Transforming Healthcare Access: Bluebird Bio s Innovative Agreement with CMMI for Sickle Cell Gene Therapy In a significant stride towards enhancing healthcare accessibility, bluebird bio, Inc. (NASDAQ: BLUE), a leading biotechnology company, has announced its collaboration with the Center for Medicare and Medicaid Innovation (CMMI) to implement an outcomes-based agreement f...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-6.67 $ |
| Revenues (TTM) |
10.66 $
|
| Cash Flow (TTM) |
- |
| Cash |
8.08 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
419,137 |
| Net
Income per Employee (TTM) |
562,250 |
| Receivable Turnover Ratio (TTM) |
- |
| Inventory Turnover Ratio (TTM) |
1.29 |
| Asset Turnover Ratio (TTM) |
0.34 |
|
|
| Per Share |
|
| Earnings (TTM) |
-6.67 $
|
| Revenues (TTM) |
10.66 $ |
| Cash Flow (TTM) |
- |
| Cash |
8.08 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
| |
| ZYNTEGLO |
|
 67.96 % |
of total Revenue |
| LYFGENIA |
|
32.04 % |
of total Revenue |
| |
On May 9 2024 the Bluebird Bio Inc provided following guidance
bluebird bio Inc. (NASDAQ: BLUE) has reported its first quarter results for 2024, highlighting the Company's operational progress and providing guidance for the year. The company is based in SOMERVILLE, Mass.
Bluebird bio has established a strong foundation in the commercial gene therapy space, with a network of qualified treatment centers (QTCs) that is considered unparalleled. The company has successfully navigated access and reimbursement challenges for patients, and there is a clear demand for their therapies from both patients and healthcare providers.
These achievements have positioned bluebird bio as a leader in the gene therapy industry, with a promising outlook for the future. The com...
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
14.94% 